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Available online 20 January 2016Background: Chronic heart failure (HF) remains a leading cause of cardiovascular (CV) mortality and morbidity
worldwide. The aim of the study was to investigate whether the pattern of angiogenic endothelial progenitor
cells (EPCs) and apoptotic endothelial cell-derived microparticles (EMPs) would be able to differentiate HF
with reduced (HFrEF) and preserved (HFpEF) ejection fraction.
Methods: One hundred sixty four chronic HF subjects met inclusion criteria. Patients with global left ventricular
ejection fraction ≥50% were categorized as the HFpEF group (n = 79) and those with ≤45% as the HFrEF group
(n = 85). Therefore, to compare the circulating levels of biological markers 35 control subjects without HF
were included in the study. All control individuals were age- and sex-matched chronic HF patients. The serum
level of biomarkers was measured at baseline. The ﬂow cytometric technique was used for predictably
distinguishing circulating cell subsets depending on expression of CD45, CD34, CD14, Tie-2, and CD309 antigens
and determining endothelial cell-derived microparticles. CD31+/annexin V+ was deﬁned as apoptotic endothelial
cell-derived MPs, MPs labeled for CD105+ or CD62E+ were determined as MPs produced due to activation of
endothelial cells.
Results: In multivariate logistic regression model T2DM (R2= 0.26; P = 0.001), obesity (R2 = 0.22; P = 0.001),
previous MI (R2 = 0.17; P = 0.012), galectin-3 (R2 = 0.67; P = 0.012), CD31+/annexin V+ EMPs (R2 = 0.11;
P = 0.001), NT-proBNP (R2 = 0.11; P = 0.046), CD14+CD309+ cells (R2 = 0.058; P = 0.001), and
CD14+СD309+ Tie-2+ cells (R2 = 0.044; P = 0.028) were found as independent predictors of HFpEF. Using
multivariate Cox-regression analysis adjusted etiology (previous myocardial infarction), cardiovascular risk
factors (obesity, type 2 diabetes mellitus) we found that NT-proBNP (OR 1.08; 95% CI = 1.03–1.12; P =
0.001) and CD31+/annexin V+ EMPs to CD14+CD309+ cell ratio (OR 1.06; 95% CI = 1.02–1.11; P = 0.02)
were independent predictors for HFpEF.
Conclusion:We found that CD31+/annexin V+ EMPs to CD14+CD309+ cell ratio added to NT-proBNP, clinical
data, and cardiovascular risk factors has exhibited the best discriminate value and higher reliability to predict
HFpEF compared with NT-proBNP and clinical data/cardiovascular risk factors alone.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Chronic heart failure (HF) remains a leading cause of cardiovascular
(CV) mortality and morbidity worldwide (Go et al., 2014). Although
over the last decades the incidence of newly HF in developed countries
have been substantially declined particularly for HFwith reduced ejectionil.com (A.E. Berezin).
. This is an open access article underfraction (HFrEF) (Gerber et al., 2015), there ismarked increase in hospital
admissions, CV and non-CV death rate predominance of HF with
preserved ejection fraction (HFpEF) (Dunlay et al., 2015; Jorge
et al., 2015). As expected, the routine use of biomarkers on diagnosis
of HFrEF andHFpEFmight help stratify the patients at higher risk of death
and clinical outcomes. In fact, both 2012 European Society of Cardiology
(ESC) Guidelines for the Diagnosis and Treatment of Acute and Chronic
Heart Failure and 2013 American College of Cardiology Foundation/
American Heart Association (ACCF/AHA) Guideline for the Managementthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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diagnosis. Indeed, the HFpEF is that one that really needs improvement of
biomarkers for diagnosis and prognosis (McMurray et al., 2012; Yancy
et al., 2013). In this context, many biological markers, which reﬂect several
faces of pathogenesis ofHF, havebeen investigated indetail, but bynowna-
triuretic peptides, soluble ST2, galectin-3, andhigh-sensitive cardiac speciﬁc
troponins were validated only. However, there was not a large body of ev-
idence regarding perspectives thatmay provide clinically useful prognostic
information both concerning the future risk of HFpEF/HFrEF manifestation
in asymptomatic subjects, the risk of fatal events and primary/re-admis-
sions in the hospital in individuals for thosehave already established symp-
tomatic acute, acutely decompensated/advanced, and chronic stable HF
related to ischemic and non-ischemic causes (D'Elia et al., 2015). It is sug-
gested that multimorbidity in HF may limit the diagnostic and predic-
tive utility of biomarkers (Chamberlain et al., 2015).
Recent studies showed that endothelium injury is common for HF
onset and development beyond etiology (Fujisue et al., 2015). Endothelial
dysfunction closely associates with activation and/or apoptosis of
endothelial cells lead to release of newly detectable circulating
biomarkers related to endothelial dysfunction called endothelial
cell-derived microparticles (EMPs) (Dignat-George and Boulanger,
2011; Burger and Touyz, 2012). Human CD34+ primitive progenitors
and CD14+ monocytic progenitors have exhibited pro-angiogenic
capacitiesmediated through increased sensitivity to vascular endothelial
growth factor and cell-to-cell cooperation via secretion of endothelial
cell-derived microparticles (Awad et al., 2006; Burger and Touyz, 2012).
Therefore, endothelial progenitor cells (EPCs) labeled as CD14+-
CD309+(VEGFR2) and CD14+CD309+(VEGFR2) Tie-2+ cells were
found a marker of endothelial dysfunction and reparation ability
(Dignat-George and Boulanger, 2011). It has been suggested that imbal-
ance between EPCs with angiogenic capacity and apoptotic EMPs
contributed in cell injury and endothelial dysfunction may reﬂect
impaired reparative phenotype that is suitable for several CV
diseases including HF (Berezin, 2015a; Berezin and Kremzer, 2015a,b;
Berezin et al., 2015a). Indeed, endogenous deﬁciency of angiopoetic
stimuli mediated by secretion of pro-inﬂammatory cytokines, neuro-
hormones, growth factors, might lead to worsening endothelium
reparation and HF progression (Singh et al., 2012; Berezin et al.,
2015b). Recently we have reported that apoptotic EMP to EPC ratio
might independently predict clinical outcomes in advanced chronic
HFrEF patients (Berezin et al., 2015c). However, whether impaired
reparative phenotype might reﬂect a development of HFpEF and
HFpEF is still not clear. The aim of the study was to investigate whether
the pattern of endothelial progenitor cells with angiogenic capacity and
apoptotic endothelial cell-derivedmicroparticleswould be able to asso-
ciate with HFpEF and HFpEF phenotypes.
2. Methods
A total of 228 subjects suspected chronic HF were selected in this
study after reviewing discharge reports. All these persons were treated
in Zaporozhye Regional Hospital, City Hospital #6, City Hospital #10,
Zaporozhye Regional Center of Cardiovascular Diseases from April
2010 to June 2015 with primary diagnosis chronic HF.
Chronic HFwas deﬁned according to contemporary criteria provided
by actual clinical recommendation (McMurray et al., 2012). HFrEF
(LVEF ≤ 45%) and HFpEF (LVEF ≥ 50%) were determined accordingly
this recommendation. T2DM was diagnosed with revised criteria
provided by American Diabetes Association when source documents
were reviewed (Executive summary, 2013). When one or more of the
following components were found (glycated hemoglobin [HbA1c]
≥6.5%; fasting plasma glucose ≥7 mmol/L; 2-h plasma glucose
≥11.1 mmol/L during an oral glucose tolerance test; a random plasma
glucose ≥11.1 mmol/L; exposure of insulin or oral anti-diabetic drugs; a
previous diagnosis of T2DM) T2DM was determined. Dyslipidemia was
checked and determined according to NCEP Adult Treatment PanelIII (National Cholesterol Education Program) (National Cholesterol
Education Program Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults, 2002).
Including criteria for selection of the HF patients in the study were
LVEF b59%, ratio of mitral peak velocity of early ﬁlling (E) to early
diastolic mitral annular velocity (E’) [E/E’] ratio N 15 units, elevated
level of serum NT-proBNP N220 pg/mL, and clinical presentation of
chronic HF. Excluding criteria were severe kidney and liver diseases;
malignancy; creatinine plasma level above 440 μmol/L; estimated GFR
index b35 mL/min/m2; brain injury within 3 months before the enroll-
ment; valvular heart disease; thyrotoxicosis; ischemic stroke; intracra-
nial hemorrhage; acute infections; surgery; trauma; pregnancy;
implanted pacemaker/deﬁbrillator/cardioverter.
The ﬂow chart representing patient in the study is reported in Fig. 1.
Among these 228 prescreened subjects, only 164 chronic HF subjects
were included in the study accordingly inclusion/exclusion criteria.
Patients with global left ventricular ejection fraction N55% were catego-
rized as the HFpEF group (n = 79) and those with ≤45% as the HFrEF
group (n = 85). Therefore, to compare the circulating levels of biologi-
cal markers 35 control subjects without HF were included in the study.
To compare EPCs and microparticles between healthy subjects, HFpEF
and HFrEF individuals control group was made. Control subjects are
deﬁned as individuals with normal global cardiac function (LVEF
N55%, E/E′ ratio b 8 units) assessed by transthoracic echocardiography
and Tissue Doppler Imaging, serum NT-proBNP level b125 pg/mL, and
without any signs and symptoms of symptomatic HF (Fig. 2).
2.1. Ethical Statement
The study protocol was approved by the local Ethics Committee
Review Board (IRB # 3/2010), State Medical University of Zaporozhye
(Ukraine) prior to the study initiation. The study complied with the
Declaration of Helsinki and voluntary informed written consent was
obtained from all patients included in this study. All individuals included
in the study have given voluntary informed written consent.
2.2. Anthropometric Measurements
Anthropometric measurements were made using standard
procedures.
2.3. Echocardiography and Doppler Imaging
Transthoracic B-mode echocardiography and Tissue Doppler
Imaging were performed according to a conventional procedure on
ACUSON scanner (Siemens, Germany) using phased probe with
modulated frequency of 2.5–5 МHz. Left ventricular end-diastolic
and end-systolic volumes, and LVEF were measured by modiﬁed
Simpson's method (Quiñones et al., 2003). E/E′ ratio was measured
using pulsed wave Tissue Doppler Imaging according contemporary
protocol (Paulus et al., 2007).
2.4. Glomerular Filtration Rate Measurement
Calculation of glomerular ﬁltration rate (GFR) was calculated by
CKD-EPI formula (Levey et al., 2009).
2.5. Blood Sampling
After an overnight fast blood sampleswere drawn in themorning (at
7–8 a.m.) into cooled silicone test tubes wherein 2 mL of 5% Trilon B
solution were added; then they were immediately centrifuged upon
permanent cooling at 6000 rpm for 10 min. Then, plasma was refriger-
ated immediately to be stored at a temperature−70 °С. All laboratory
tests were performed using standard methods to measure the serum
fasting plasma glucose, fasting lipid proﬁles and other biomarkers.
Fig. 1. The ﬂow chart representing patients in the study.
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measured by immunoelectrochemoluminescent assay using sets by
R&D Systems (USA) on Elecsys 1010 analyzer (Roche, Mannheim,
Germany). High-sensitive C-reactive protein (hs-CRP) was measured
by commercially available standard kit (R&D Systems GmbH,
Wiesbaden-Nordenstadt, Germany). Galectin-3 was measured using
an ELISA kit (BGMedicine, Germany). Concentrations of total cholester-
ol (TC), cholesterol of high-density lipoproteins (LDL-C), and cholester-
ol of high-density lipoproteins (HDL-C) were measured by enzymatic
colorimetric method according standardized methodology on Beckman
Synchron LX20 chemistry analyzer.
2.6. Assay of Circulating Endothelial Progenitor Cell Subsets
The ﬂow cytometric technique (FCT) was used for predictably
distinguishing circulating cell subsets, which depend on expression of
CD45, CD34, CD14, Tie-2, and CD309 (VEGFR2), using High-deﬁnitionFig. 2. The sample of ﬂow cytometry picture represented CD14+CDFluorescence Activated Cell Sorter (HD-FACS) methodology (Tung
et al., 2004). Accordingly, the cells were labeled on the basis of their
forward scatter characteristic (FSC) and side scatter characteristic
(SSC) proﬁles, and standardize and calibrate instruments, ﬂuorescence
and light scatter resolution, and sensitivity were determined according
to standard protocol (Hoffman, 2005).
The cells were directly stained and analyzed for phenotypic
expression of surface proteins using anti-humanmonoclonal antibodies,
including anti-CD45 FITS (BD Biosciences, San Jose, CA, USA), anti-CD34
FITS (BD Biosciences), anti-VEGFR-2 known as anti-CD309 (BD Biosci-
ences), anti-Tie-2 (BD Biosciences) and anti-CD14 (BD Biosciences).
The ﬂuorescence minus one technique was used to provide negative
controls and establish positive stain boundaries. After lysis of erythro-
cytes with Utilize wash solution, the samples were centrifuged at
200 ×g for 15 min. Then the samples were washed twice with PBS and
ﬁxed immediately. Double- or triple-positive events were determined
using Boolean principles (“and”, “not”, “or”, etc.).309+ cells (panel A) and CD31+/annexin V+ EMPs (panel B).
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Circulating EPCs were deﬁned as CD34/СD309 (VEGFR2) positive
cells with lack of CD45 expression. From each tube 500,000 events
were analyzed. For CD14+ populations, co-expression with Tie-2- and/
or VEGFR-2- was determined using quadrant analysis. Standardized cell
counts were presented as a percentage of the total of the white blood
cell count, identiﬁed as the total number of all CD45+ cells. The
FITC-labeled isotype control was analyzed with the same gate and
window settings. Pro-angiogenic phenotype for EPCs was determined
as CD14+СD309+ (VEGFR2) Tie-2+ antigen presentation. The repro-
ducibility of EPC measurements using the standard protocol was 3.5%.
2.8. Assay of Circulating Microparticles
Circulating MPs were isolated from 5 mL of venous citrated blood
drawn from the ﬁstula-free arm. To prevent contamination of samples
platelet-free plasma (PFP) was separated from whole blood. PFP was
centrifuged at 20,500 × rpm for 90 min. MP pellets were washed with
DMEM (supplemented with 10 μg/mL polymyxin B, 100 UI of strepto-
mycin, and 100 U/mL penicillin) and centrifuged again (20,500 rpm
for 60 min). The obtained supernatant was extracted, and MP pellets
were re-suspended into the remaining 200 μL of supernatant. PFP,
MPs, and supernatant were diluted ﬁve-, 10-, and ﬁve-fold in PBS,
respectively. Only 100 μL of supernatant was prepared for further anal-
ysis through incubation with different ﬂuorochrome-labeled antibodies
or their respective isotypic immunoglobulins (Beckman Coulter).
2.9. Determination of Endothelial Cell-derived Microparticles
MPs were labeled and characterized by ﬂow cytometry technique
per HD-FACS (High-deﬁnition Fluorescence Activated Cell Sorter)
methodology independently after supernatant diluted without freeze
(Orozco and Lewis, 2010). Two size gates were deﬁned based on
forward angle light scattering from polystyrene microsphere (0.5–
0.9 μm) according to standard protocol (Shah et al., 2008). Accordingly,
MPs' gate was deﬁned less than a 0.4 μm polystyrene microsphere
extending down to the noise threshold level that is equivalent to cell-
derived MPs b1 μm diameter (Lacroix et al., 2010).
CD31 antigen was determined as essential marker for endothelial
cells. CD31+/annexin V+ was deﬁned as apoptotic endothelial cell-
derived MPs, MPs labeled for CD105+ or CD62E+ were determined as
MPs produced due to activation of endothelial cells (Lacroix et al.,
2013).We used anti-CD31 [(platelet endothelial cell adhesionmolecule
[PECAM]-1)]-phycoerythrin (PE; 20 μL/test), anti-CD62E [E-selectin]-
FITC (20 μL/test) antibodies obtained from Beckman Coulter. MPs
that expressed phosphatidylserine were labeled using ﬂuorescein-
conjugated Annexin V solution (20 μL/test; BD Biosciences, USA) in
the presence of CaCl2 (5 mM) according to the recommendation of
the supplier.
The samples were incubated in the dark for 15min at room temper-
ature according to the manufacturer's instructions. The analysis of area,
height, and width forward scatter (FSC) and side scatter (SSC) parame-
ters was performed as well as side scatter width (SSC-W). The gate for
MPs was deﬁned by size, using 0.5 and 1.0 μm beads (Sigma, St Louis,
MO, USA). For each sample, 500 thousand events have been analyzed.
Compensation tubes were used with similar reagents as were used in
the sample tubes. Datawere constructed as numerous ofMPs depending
on marker presentation (positive or negative) and determination of MP
populations.
Calculation of the number of MPs per liter plasma was based upon
the particle count per unit time, the ﬂow rate of the ﬂow cytometer,
and the net dilution during sample preparation of the analyzed MP
suspension. MP-exposed antigen concentrations were calculated in
each sample by multiplying the total concentration of positive MPs by
the mean ﬂuorescence intensity of the antigen exposure of the totalpositive MP population. The reproducibility of EPCs using standard
protocol was 4.5%.
2.10. Statistical Analysis
Data were analyzed using SPSS 20.0 (SPSS, IBM Corporation, NY,
USA) and Prism v.6 (GraphPad Software Inc., La Jolla, CA, USA). Quanti-
tative variables were expressed as mean (M) and standard deviation
(±SD), median and interquartile range (IQR), estimated marginal
mean (95% conﬁdence interval [CI]) or number (percentage). An inde-
pendent group t-test was used to compare all the interval parameters
matching the criteria of normality and homogeneity of variance. For
interval parameters that fail to match these criteria, the non-parametric
Mann–Whitney test was used to compare variables. Categorical variables
and frequencies were compared using Chi2 test and Fisher exact test of
independence. Comparisons of control groupwith a combinedpopulation
of both HF groups are done using ANOVA. The potential factors that may
be associatedwithHFpEFwere identiﬁedﬁrstwith the univariate analysis
(ANOVA), and then the independent predictors of HFpEF were searched
with the multivariate one-step backward logistic regression analysis,
initially including variables for which a P value of b0.1 was achieved
from the univariate analysis. R2, B-coefﬁcient were calculated for all
regression models. The odds ratio (OR) and 95% CI were calculated for
factors independently predicted HFpEF vs HFrEH in Cox-regression
model. For each model that is able to differentiate HFpEF from HFrEF OR
(95% CI) and AUC [Area Under Curve] (95% CI) were calculated. A
calculated difference of P b 0.05 was considered signiﬁcant.
3. Results
The study population consisted of 164 HF subjects (86 males and 78
females), with mean age of 52.13 ± 7.80 years, and 35 healthy volun-
teers as control for biomarker examination. All control individuals
were age- and sex-matched chronic HF patients. The baseline data of
eligible individuals are listed in Table 1. We did not ﬁnd any signiﬁcant
difference between both HF cohorts in age, sex, NYHA class representa-
tion, hypertension, adherence to smoke, bodymass index (BMI), systol-
ic and diastolic blood pressure (BP) and heart rate. Previous myocardial
infarction (MI), dilated cardiomyopathy, dyslipidemiawere determined
frequently in subjects with HFrEF compared with persons with HFpEF.
Contrary, obesity, and type 2 diabetes mellitus (T2DM) patients were
found frequently in patients with HFpEF then in HFpEF patient cohort.
Subjects with HFrEF compared with HFpEF have demonstrated
higher levels of creatinine, total cholesterol, high-density lipoproteins,
uric acid, NT-proBNP, galectin-3, and lower estimated GFR and hemo-
globin (Table 2). However, level of circulating biomarkers have sufﬁ-
ciently differenced between healthy volunteers and HF group patients
apart from hemoglobin. Therefore, numerous of CD14+CD309+ cells
were signiﬁcantly higher (P = 0.001) in HFpEF patient cohort than in
HFrEF patient cohort. Contrary, HFpEF patients have exhibited lower
levels of CD31+/annexin V+ EMPs comparedwith HFrEF patients. How-
ever, healthy volunteers have exhibited a lower level of CD31+/annexin
V+ EMPs compared with entire HF patient cohort and both HFpEF and
HFrEF individuals. There were not found signiﬁcant changes between
HF cohorts in numerous of CD14+СD309+ Tie-2+ cells and CD62E+
EMPs, while in the control healthy subjects the level of both biomarkers
was signiﬁcantly higher.
Table 3 is reported the concomitant study medication. As one can
see, all HF patients were treated with ACE inhibitors or ARBs in com-
bination with loop diuretics. Proportions of the beta-blocker treated
patients in both HF cohorts were similar. Aspirin, ivabradine, mineralo-
corticoid receptor antagonists, and statins were used frequently in
HFrEF subjects. Contrarily, metformin and anti-platelet drugs distin-
guished as aspirin were prescribed frequently in HFpEF patients.
We did not ﬁnd any sufﬁcient association between CD14+CD309+
cells, CD14+СD309+ Tie-2+ cells, CD31+/annexin V+ EMPs, CD62E+
Table 1
The characteristics of participants in the study.
Variables Healthy volunteers
(n = 35)
Entire patient group
(n = 164)
P value between healthy
volunteers and entire HF group
Subjects with HFrEF
(n = 85)
Subjects with HFpEF
(n = 79)
P value between
HF cohorts
Age, years 54.85 ± 5.20 56.13 ± 7.80 0.44 57.50 ± 6.70 54.79 ± 6.62 0.78
Male 18 (51.4%) 86 (52.4%) 0.24 49 (57.6%) 37 (46.8%) 0.24
II NYHA class – 57 (34.8%) – 29 (34.1%) 28 (35.4%) 0.96
III NYHA class – 65 (39.6%) – 36 (42.4%) 29 (36.7%) 0.66
IV NYHA class – 42 (25.6%) – 20 (23.5%) 22 (27.8%) 0.84
Previous MI – 112 (62.3%) – 66 (77.6%) 46 (58.2%) 0.01
Dilated cardiomyopathy – 21 (12.8%) – 18 (21.2%) 3 (3.8%) 0.001
Hypertension – 104 (63.4%) – 53 (62.4%) 51 (64.6%) 0.88
Dyslipidemia – 116 (70.7%) – 68 (80.0%) 48 (70.8%) 0.01
T2DM – 38 (23.2%) – 15 (17.6%) 23 (29.1%) 0.01
Obesity – 62 (37.8%) – 26 (30.5%) 36 (45.6%) 0.01
Adherence to smoke 9 (25.7%) 35 (21.3%) 0.68 18 (21.2%) 17 (21.5%) 0.98
BMI, kg/m2 22.3 (20.1–23.5) 24.5 (21.2–28.9) 0.01 22.5 (20.6–25.2) 25.1 (20.7–27.6) 0.72
Systolic BP, mm Hg 121 ± 4 132 ± 9 0.01 130 ± 7 133 ± 6 0.88
Diastolic BP, mm Hg 68 ± 4 77 ± 6 0.01 76 ± 5 78 ± 5 0.88
Heart rate, beat per min 70.25 ± 4.12 72.35 ± 6.95 0.88 76.20 ± 5.11 66.70 ± 5.24 0.12
LVEF, % 67.2 (61.9–72.8) 45.5 (30.4–55.3) 0.01 36.50 (30.7–42.1) 55.1 (50.9–58.4) 0.026
Notes: Data are expressed asmean (M) and standarddeviation (±SD), numerous (n) and frequencies (%). Comparisons of control groupwith a combinedpopulation of bothHFgroups are
done using ANOVA. Statistical comparisons between both HF groups are made using Mann–Whitney test with signiﬁcance levels of b0.05 (for 2-tailed).
Abbreviations: NYHA — New York Heart Association; T2DM — type 2 diabetes mellitus, MI — myocardial infarction; LVEF — left ventriculat ejection fraction.
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healthy volunteers. However, there were signiﬁcant associations
between CD31+/annexin V+ EMPs with adherence to smoke (r =
0.31; P = 0.001) in healthy individuals.
In HFrEF cohort serumgalectin-3 associated positively NYHA class of
CHF (r = 0.27, P = 0.001), CD31+/annexin V+ EMPs (r = 0.23; P =
0.001), and negatively with CD14+CD309+ cells (r = −0.28; P =
0.003), CD14+СD309+ Tie-2+ cells (r = −0.23; P = 0.001), GFR
(r =−0.23; P = 0.001), hemoglobin (r =−0.21; P = 0.001). There-
fore, NT-pro-BNP positively associated with NYHA class of CHF (r =
0.43, P = 0.001), CD31+/annexin V+ EMPs (r = 0.23; P = 0.001), and
negatively with LVEF (r = −0.43, P = 0.001), GFR (r = −0.28; P =
0.001), obesity (r =−0.25; P = 0.001).Table 2
The biomarkers in the patient study population.
Variables
Healthy volunteers
(n = 35)
Entire patient cohort
(n = 164)
P value between
volunteers and e
GFR, mL/min/1.73 m2 112.4 (102.2–123.4) 82.3 (68.7–102.6) 0.01
Hemoglobin, g/L 138.3 (129.8–151.2) 135.4 (128.5–142.1) 0.94
Fasting glucose,
mmol/L
4.24 (3.6–4.9) 5.17 (3.5–9.6) 0.01
HbA1c, % 4.78 (4.2–5.15) 6.8 (4.1–9.5) 0.01
Creatinine, μmol/L 65.4 (58.2–81.2) 72.3 (58.7–92.6) 0.01
Total cholesterol,
mmol/L
4.56 (3.25–4.88) 5.1 (3.9–6.1) 0.01
HDL cholesterol,
mmol/L
1.03 (0.98–1.08) 0.92 (0.88–1.13) 0.01
LDL cholesterol,
mmol/L
2.77 (2.33–3.10) 3.23 (3.11–4.40) 0.01
Uric acid, μmol/L 295 (210–367) 345 (253–420) 0.06
NT-pro-BNP, pg/mL 33.1 (18.3–63.6) 2336.2 (988.5–3552.8) 0.001
hs-CRP, mg/L 3.27 (0–5.33) 7.10 (6.25–8.20) 0.001
Galectin-3, μg/L 4.36 (0.98–9.37) 18.92 (14.25–23.15) 0.001
CD14+CD309+,
cells/μL
0.426 (0.370–0.574) 0.296 (0.225–0.351) 0.001
CD14+СD309+
Tie-2+, cells/μL
0.0465 (0.0253–0.0710) 0.032 (0.025–0.410) 0.001
CD31+/annexin V+
EMPs, n/mL
0.154 (0.03–0.21) 0.48 (0.29–0.64) 0.001
CD62E+ EMPs, n/mL 1.35 (0.95–1.68) 0.98 (0.87–1.12) 0.001
Note: The values correspond tomedians and IQR of 25%–75%. Comparisons of control groupwit
between both HF groups are made using Mann–Whitney test with signiﬁcance levels of b0.05
Abbreviations: GFR— glomerular ﬁltration rate; BMP— brain natriuretic peptide; BP— blo
endothelial cell-derived microparticles; EPCs — endothelial progenitor cells; HbA1c — glyIn HFpEF galectin-3 positively associated with type 2 diabetes
mellitus (r = 0.26; P = 0.001), CD31+/annexin V+ EMPs (r = 0.23;
P = 0.002), and negatively with CD14+CD309+ cells (r = −0.32;
P = 0.001), CD14+СD309+ Tie-2+ cells (r =−0.29; P = 0.001). NT-
pro-BNP positively associated with NYHA class of CHF (r = 0.36, P =
0.002), CD31+/annexin V+ EMPs (r= 0.23; P = 0.001), and negatively
with LVEF (r =−0.28, P = 0.001), CD14+CD309+ cells (r =−0.26,
P = 0.003), obesity (r = −0.24, P = 0.001). Additionally, hs-CRP
associated signiﬁcantly with type 2 diabetes mellitus (r = 0.22;
P = 0.001) in entire group of HF patients. No associations between
numerous EPCs and EMPs with medications were found.
In multivariate logistic regression model type 2 diabetes mellitus
(R2 = 0.26; P = 0.001), obesity (R2 = 0.22; P = 0.001), previous MIhealthy
ntire HF group
Subjects with
HFrEF (n = 85)
Subjects with
HFpEF (n = 79)
P value between
HF cohorts
79.6 (63.1–92.3) 88.2 (77.1–102.1) 0.046
128.1 (124.2–133.1) 138.5 (126.2–141.8) 0.001
4.98 (3.8–8.1) 5.27(3.6–9.3) 0.28
6.4 (4.6–8.0) 6.9 (4.3–9.2) 0.22
82.1 (64.9–90.5) 67.7 (59.1–84.1) 0.01
5.3 (4.6–6.0) 5.0 (3.5–5.9) 0.02
0.97 (0.92–1.08) 0.88 (0.83–1.03) 0.042
3.71 (3.50–4.20) 3.50 (3.10–3.96) 0.05
357 (253–412) 311 (206–369) 0.01
2774.5 (1520.4–3870.2) 2130.8 (954.5–3056.2) 0.02
7.05 (6.09–8.03) 7.14 (6.22–8.32) 0.46
19.03 (15.80–23.96) 16.99 (13.77–19.20) 0.022
0.236 (0.202–0.325) 0.325 (0.233–0.407) 0.001
0.030 (0.021–0.403) 0.036 (0.019–0.465) 0.26
0.59 (0.42–0.65) 0.32 (0.25–0.43) 0.001
1.02 (0.81–1.25) 0.96 (0.82–1.17) 0.66
h a combined population of both HF groups are done using ANOVA. Statistical comparisons
(for 2-tailed).
od pressure; LVEF— left ventricular ejection fraction; BMI— body mass index, EMPs—
cated hemoglobin, HDL — high-density lipoprotein; LDL — low-density lipoprotein,
Table 3
The medications in the patient study population.
Entire patient cohort (n = 164) Subjects with HFrEF (n = 85) Subjects with HFpEF (n = 79) P value
ACE inhibitors or ARBs, n (%) 164 (100%) 85 (100%) 79 (100%) 1.0
Aspirin, n (%) 128 (78.0%) 77 (90.5%) 51 (64.6%) 0.022
Other anti-platelet drugs, n (%) 36 (22.0%) 8 (9.5%) 28 (35.4%) 0.001
Beta-adrenoblockers, n (%) 135 (82.3%) 71 (83.5%) 64 (81.0%) 0.76
Dihydropyridine calcium channel blockers, n (%) 27 (16.5%) 15 (17.7%) 12 (15.2%) 0.24
Ivabradine, n (%) 48 (29.3%) 38 (44.7%) 10 (12.7%) 0.001
Mineralocorticoid receptor antagonists, n (%) 57 (34.8%) 43 (50.5%) 14 (17.7%) 0.001
Loop diuretics, n (%) 164 (100%) 85 (100%) 79 (100%) 0.043
Statins, n (%) 116 (70.7%) 68 (80.0%) 48 (70.8%) 0.01
Metformin, n (%) 38 (23.2%) 15 (17.6%) 23 (29.1%) 0.01
Sitagliptin, n (%) 21 (12.8%) 9 (10.6%) 12 (15.2%) 0.12
Notes: Data are expressed as numerous (n) and frequencies (%). Comparisons of control group with a combined population of both HF groups are done using ANOVA.
Abbreviations: ACE — angiotensin-converting enzyme; ARBs— angiotensin-2 receptor blockers.
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annexin V+ EMPs (R2 = 0.11; P = 0.001), NT-proBNP (R2 = 0.11;
P = 0.046), CD14+CD309+ cells (R2 = 0.058; P = 0.001), and
CD14+СD309+ Tie-2+ cells (R2 = 0.044; P = 0.028) were found as
independent predictors of HFpEF (Table 4).
Using multivariate Cox-regression analysis adjusted etiology
(previous myocardial infarction), cardiovascular risk factors (obesity,
type 2 diabetes mellitus) we found that NT-proBNP (OR 1.08; 95%
CI = 1.03–1.12; P = 0.001) and CD31+/annexin V+ EMPs to
CD14+CD309+ cell ratio (OR 1.06; 95% CI = 1.02–1.11; P = 0.02)
were independent predictors for HFpEF (Table 5).
Then we have compared various predictive models based on
clinical data, cardiovascular risk factors, and biomarkers. We found
that Model 7 constructed on combination of standard model + NT-
proBNP + CD31+/annexin V+ EMPs to CD14+CD309+ cell ratio has
exhibited the best discriminative value and reliability to predict HFpEF
(Table 6).
4. Discussion
The results of our study have revealed for the ﬁrst time that combi-
nation of NT-proBNP and CD31+/annexin V+ EMPs to CD14+CD309+
cell ratio is a useful biomarker for chronic HF, which contributes in theTable 4
An association of demographics, risk factors and biomarkers with dependent variable:
HFpEF. The results of univariate and multivariate one-step backward logistic regression
models.
Variables
Univariate logistic
regression model
Multivariate logistic
regression model
R2 B-coefﬁcient
P
value
R2 B-coefﬁcient
P
value
Previous MI 0.19 3.77 0.001 0.17 2.05 0.012
Dilated
cardiomyopathy
0.05 0.135 0.26 –
Obesity 0.27 9.23 0.001 0.22 8.97 0.001
GFR 0.053 −0.017 0.18 –
T2DM 0.26 11.92 0.003 0.26 9.54 0.001
Hemoglobin 0.04 −0.036 0.56 –
hs-CRP 0.073 0.98 0.044 0.057 0.54 0.12
NT-proBNP 0.19 6.24 0.001 0.11 5.12 0.046
Galectin-3 0.09 3.15 0.001 0.67 2.97 0.012
CD14+CD309+ cells 0.096 −1.47 0.003 0.058 −2.14 0.001
CD14+СD309+
Tie-2+ cells
0.084 −2.55 0.001 0.044 −1.06 0.028
CD31+/annexin
V+ EMPs
0.12 3.25 0.001 0.12 2.97 0.001
CD62E+ EMPs 0.063 −0.37 0.044 0.058 −0.22 0.26
Abbreviations: T2DM— type 2 diabetes mellitus, GFR— glomerular ﬁltration rate; BMP—
brain natriuretic peptide; LVEF — left ventricular ejection fraction; EMPs — endothelial
cell-derived microparticles; EPCs— endothelial progenitor cells.differentiation of HFpEF from HFrEF. We have demonstrated that HF
patients have exhibited elevated levels of EPCs with angiopoetic capac-
ities, apoptotic-derived EMCs, as well as decreased level of CD62E+
EMPs secreted by activated endothelial cells. Recently higher level of
CD62+ EMP secreted from activated endothelial cells in the healthy
subjects versus HF patients was related to rather endothelial dysfunc-
tion than endothelial cell injury) (Dignat-George and Boulanger,
2011; Burger and Touyz, 2012). In our study we did not ﬁnd any signif-
icance changes between HFrEF and HFpEF patients, probably due to
similar molecular mechanisms that might lead to endothelial cell
activation.We have suggested that lack of sufﬁcient difference between
co-morbidities' presentation among HFrEF and HFpEF groups might
express similar ﬁnding. Interestingly, because of the number of existing
CV risk factors which are variable between HF patients, simple EPC
counts do not adequately describe vascular disease risk in all clinical
conditions and, as such, the CV risk remains (Sen et al., 2011). However,
the imbalance in pattern of circulating EMPs and EPCs might affect
endothelium ability to repair and previously we have described similar
changes as “impaired” phenotype (Berezin, 2015b). The concept of
“impaired” phenotype as imbalance between factors originating from
endothelium with innate angiogenic and/or injury capacities directly
contributed in the endothelial dysfunction and requires further investi-
gation because the molecular mechanism of their release into circula-
tion still remains elusive.
Because biomarkers' levels might suggest different amounts of acti-
vation of several pathophysiological pathways between HFpEF and
HFrEF development (Sanders-van Wijk et al., 2015; Kaila et al., 2012),
we have hypothesized that numerous apoptotic EMPs to EPCs might
be distinguished in HFpEF and HFpEF individuals. It is important to
note that recent clinical studies have shown increased serum level of
NT-proBNP as powerful predictive factor in both HFpEF and HFrEF,
although patients with HFpEF exhibits lower NT-proBNP levels (Kang
et al., 2015). Several biomarkers, i.e. soluble suppression of tumorige-
nicity 2 protein, galectin-3, cardiac speciﬁc troponins, provides robust
prognostic information in HFrEF, but not for HFpEF, while they could
improve the prognostication pattern via adding toNT-proBNP in predic-
tivemodel (Friões et al., 2015). In the LUdwigshafen Risk and Cardiovas-
cular Health (LURIC) study high-sensitive C-reactive protein was found
to be an independent and strong predictor of mortality in HFpEF (Koller
et al., 2014), but this biomarker even after adding to predictive model
based on NT-proBNP was not able to predict HFpEF development.
Overall, discriminative values of several cardiac biomarkers including
NT-proBNP to stratify patients with HFpEF and HFrEF are not fully
adequate.
Apoptotic EMPs are considered a marker of endothelial cell injury
and a factor that contributed in transferring biological information,
active molecules, hormones, proteins, lipid components, as well as
regulating cell homeostasis and cell response (Sansone et al., 2015;
Bank et al., 2015). Interestingly, apoptotic EMPs may directly injure
endothelium (Montoro-García et al., 2015). In contrast, EPCs labeled
Table 5
Predictive value of biomarkers on dependent variable: HFpEF vsHFrEF. The Cox-regression analysis adjusted etiology (previousmyocardial infarction), cardiovascular risk factors (obesity,
type 2 diabetes mellitus).
Variables
Univariate Cox regression Multivariate Cox regression
OR 95% CI P value OR 95% CI P value
NT-proBNP 1.12 1.06–1.27 0.001 1.08 1.03–1.12 0.001
Galectin-3 1.08 1.03–1.12 0.002 1.04 1.00–1.09 0.12
CD31+/annexin V+ EMPs to CD14+CD309+ cell ratio 1.09 1.04–1.16 0.001 1.06 1.02–1.11 0.02
CD31+/annexin V+ EMPs 1.04 1.01–1.09 0.024 1.02 0.98–1.04 0.26
CD31+/annexin V+ EMPs to CD14+CD309+Tie-2+ cell ratio 1.05 1.02–1.09 0.002 1.04 1.00–1.09 0.064
CD14+CD309+ cells 1.04 1.01–1.06 0.044 1.02 0.99–1.05 0.34
CD14+СD309+ Tie-2+ cells 1.03 1.00–1.05 0.12 –
Abbreviations: OR— odds ration; BMP — brain natriuretic peptide; EMPs — endothelial cell-derived microparticles.
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action; they are capable of repairing endothelium and restoring of
endothelial function (Sandri et al., 2015; Berezin and Kremzer, 2015a,
b). In this context, decreased CD31+/annexin V+ EMPs and increased
CD14+CD309+ cells might elucidate reparative ability of endothelium.
Recent clinical studies have shown that numerous of EPCs deﬁned as
CD34+ CD309+ have failed to associate with CV risk factors, medica-
tions, HF etiology, age or gender of the patients,while low EPCs' number
was associatedwith an increased likelihood of abnormal left ventricular
mass and worse cardiac remodeling (Michelucci et al., 2015; António
et al., 2014). Numerous of CD31+/annexin V+ EMPs strongly correlate
with endothelial function and CV outcomes in stable CAD patients
(Sinning et al., 2011; Werner et al., 2006). Moreover, Huang et al.
(2010) reported that increased circulating CD31+/annexin V+ EMPs
and decreased circulating EPCs predict target organ damage in hyper-
tensive patients. In our study HFpEF patients have exhibited lower
CD31+/annexin V+ EMPs to CD14+CD309+ cell ratio and CD31+/
annexin V+ EMPs to CD14+CD309+Tie-2+ cell ratio in comparison
with HFrEF patients. The result of Cox-regression analysis adjusted
etiology (previous myocardial infarction), cardiovascular risk factors
(obesity, type 2 diabetes mellitus) has revealed that NT-proBNP and
CD31+/annexin V+ EMPs to CD14+CD309+ cell ratio are independent
predictors of HFpEF. Additionally, we found that the discriminative
value of NT-proBNP as a HF diagnostic biomarker might improve by
use in combination with CD31+/annexin V+ EMPs to CD14+CD309+
cell ratio, whereas increased number of CD31+/annexin V+ EMPs
alone and decreased number of CD14+CD309+ cells alone were not
able to improve the discriminative value of standard models based on
combination of clinical features (previousmyocardial infarction, obesity,
type 2 diabetes mellitus) or NT-proBNP.
However, it is assumed to take into consideration the high costs of
the of CD31+/annexin V+ EMPs to CD14+CD309+ cell ratio versus
traditional circulating biomarkers' assessment using ELISA tests.
Probably, this might be a limitation for a wide implementation of the
assay in the routine clinical practice, although clinical utility of expected
results is not completely determined and in future similar investigationsTable 6
Comparison of predictive value of models expressed HFpEF vs HFrEF.
Models
Model 1 (standard model)
Model 2: NT-proBNP
Model 3: standard model + NT-proBNP
Model 4: CD31+/annexin V+ EMPs to CD14+CD309+ cell ratio
Model 4: standard model + CD31+/annexin V+ EMPs to CD14+CD309+ cell ratio
Model 6: NT-proBNP + CD31+/annexin V+ EMPs to CD14+CD309+ cell ratio
Model 7: standard model + NT-proBNP + CD31+/annexin V+ EMPs to CD14+CD309+ ce
Note: Standard model — previous myocardial infarction, obesity, type 2 diabetes mellitus.
Abbreviations: OR— odds ration; AUC — area under curve; CI— conﬁdence interval; BMP — bmight consider as an essential tool for prediction and probably individu-
alized medical care in predominantly patients with HFpEF.
Thus, there is a large body of evidence regarding participation of
angiogenic EPCs and apoptotic EMPs in the regulation of cardiac
regeneration and endothelial function. The results reﬂect the role
of imbalance between angiopoetic EPCs and apoptotic EMPs in HF
development, in particular an ability of CD31+/annexin V+ EMPs to
CD14+CD309+ cell ratio to improve the discriminative value of
NT-proBNP to associate with HFpEF vs HFrEF was found. We believe
that this novel biomarkers' approach could become highly relevant
for providing effect to risk stratify patients with HFpEF. Probably,
biomarkers that reﬂect reparative capacity of endotheliummay support
diagnostic strategies in subpopulations of patients with chronic HF. The
identiﬁcation of these biomarkers might be useful for monitoring
disease progression and potential therapeutic targets. To assay well
balanced cutoff points regarding NT-proBNP and CD31+/annexin V+
EMPs to CD14+CD309+ cell ratio as predictors of HFpEF, more investi-
gations are required.
Conclusion: CD31+/annexin V+ EMPs to CD14+CD309+ cell ratio
was added to NT-proBNP, clinical data, and cardiovascular risk factors
have exhibited the best discriminate value and higher reliability to pre-
dict HFpEF compared with NT-proBNP and clinical data/cardiovascular
risk factors alone.
5. Study Limitations
This study has some limitations. The ﬁrst limitation affects the
methods of isolation and determination of EMPs and EPCs. Although
HD-FACS methodology is widely used, this method is not standardized.
Therefore, there are some overlaps between centrifugation velocity and
further determination of EMPs that might reﬂect some obstacles for
results' interpretation.Moreover, annexin V binding byMPs is a calcium
dependent process and the marker has a limited role in assessment of
apoptotic MPs. However, annexin V+ MPs remain a well investigated
marker of comprehensive description of apoptotic-derived MPs
received from peripheral blood in healthy individuals as well as in HFOR 95% CI P value AUC 95% CI P value
1.05 1.02–1.08 0.001 0.62 0.59–0.66 0.044
1.08 1.03–1.12 0.001 0.68 0.61–0.74 0.012
1.11 1.06–1.17 0.001 0.71 0.65–0.79 0.001
1.06 1.02–1.11 0.02 0.69 0.63–0.76 0.016
1.12 1.05–1.21 0.001 0.73 0.64–0.81 0.001
1.10 1.04–1.17 0.001 0.70 0.63–0.76 0.001
ll ratio 1.17 1.10–1.25 0.001 0.81 0.69–0.93 0.001
rain natriuretic peptide; EMPs — endothelial cell-derived microparticles.
93A.E. Berezin et al. / EBioMedicine 4 (2016) 86–94patients. The next limitation is a small cohort of patients included in
the study. Therefore, we used regression models for adjusted clinical
data, CV risk, previous MI, metabolic co-morbidities, to analyze the
discriminative ability of NT-proBNP alone, CD31+/annexin V+
EMPs to CD14+CD309+ cell ratio alone and their combination as
predictors of HFpEF. Greater cohort patients in observation study
might help increase statistical power. The high cost of the biomarker
assaymight be considered as a limitation of the study as of now. Further
investigations with a greater cohort of patients explaining the role of
novel biomarker to differentiate both phenotypes of chronic HF are
required. The authors suppose that these restrictions might have no
signiﬁcant impact on the study data interpretation.
Abbreviations
ACEI angiotensin-converting enzyme inhibitors
ARBs angiotensin receptor blockers,
AUC area under curve
BMI body mass index
BNP brain natriuretic peptide
CHF chronic heart failure
CV cardiovascular
EMPs endothelial cell-derived microparticles
HF heart failure
HFpEF chronic HF with preserved ejection fraction
HFrEF chronic HF with reduced ejection fraction
GFR glomerular ﬁltration rate
hs-CRP high-sensitive C-reactive protein
HDL-C high-density lipoprotein cholesterol
LDL-C low-density lipoprotein cholesterol
LVEF left ventricular ejection fraction
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